Transcriptional Regulation of Tumor Necrosis Factor-alpha by Human Immunodeficiency Virus-1 Vpr by O'Leary, Shaylee Marie
 TRANSCRIPTIONAL REGULATION OF TUMOR NECROSIS FACTOR-alpha BY 
HUMAN IMMUNODEFICIENCY VIRUS-1 VPR 
 
 
 
 
 
 
 
 
by 
Shaylee M. O’Leary 
             BS in Biology, The Pennsylvania State University, 2006 
 
 
 
 
 
 
 
 
 
Submitted to the Graduate Faculty of 
The Department of Infectious Diseases and Microbiology 
The Graduate School of Public Health in partial fulfillment  
of the requirements for the degree of 
Master of Science 
 
 
 
 
 
 
 
 
 
University of Pittsburgh 
2008 
 ii 
UNIVERSITY OF PITTSBURGH 
GRADUATE SCHOOL OF PUBLIC HEALTH 
 
 
 
 
 
 
 
 
This thesis was presented 
 
by 
 
 
Shaylee M. O’Leary 
 
 
 
It was defended on 
June 2, 2008 
and approved by 
YuanPu Di, PhD, Assistant Professor, Environmental and Occupational Health, 
Graduate School of Public Health, University of Pittsburgh 
       Jeremy Martinson, PhD, Assistant Professor, Infectious Diseases and Microbiology 
                                                      Graduate School of Public Health, University of Pittsburgh
                  Thesis Director: Velpandi Ayyavoo, PhD, Assistant Professor, Infectious Diseases and 
                       Microbiology, Graduate School of Public Health, University of Pittsburgh 
 
 
 iii 
Copyright © by Shaylee M. O’Leary 
2008 
 iv 
 
HIV-1 Vpr is known to regulate both viral and host cellular promoters resulting in transcriptional 
regulation of various cellular factors in host immune cells, such as T cells, macrophages and 
dendritic cells.  It has been shown that Vpr has a role in the upregulation of proinflammatory 
cytokine TNF-α, which affects immune regulation during infection. However, the mechanisms 
by which TNF-α is regulated by HIV-1 Vpr are not well understood.  A goal of this project is to 
determine the effects of Vpr in its biologically relevant forms and identify the domains of Vpr 
involved in TNF-α production. Additionally, we also sought to determine whether TNF-α is up-
regulated in infected/exposed cells and/or bystander cells. From our experiments, we conclude 
that HIV-1 Vpr increases TNF-α production in the context of infection as well as exposure in the 
absence of other viral proteins. Furthermore, HIV-1 Vpr has multiple domains capable of 
inducing TNF-α production. However, the increase in TNF-α production in DC is dependent on 
LPS stimulation. We were unable to conclusively determine the cell type that is responsible for 
this observed phenotype however the results from our studies indicate that infected/exposed cells 
could be the dominant producers. 
 
Due to the association of Vpr with transcriptional regulation of various cellular factors, we 
investigated the domains of the TNF-α promoter involved in Vpr-mediated TNF-α regulation.  
Using the HeLa T4 cell line, TNF-α promoter mediated transactivation was increased by two 
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fold when exposed to HIV-1 Vpr(+) as opposed to HIV-1 Vpr(-) as detected by luciferase 
reporter assay. A six fold increase was observed in the transactivation of full length and mutant 
TNF-α promoter in macrophage-derived microglia cell line in the presence of Vpr expression.  
Results from mapping studies indicate that HIV-1 Vpr can regulate TNF-α production via 
multiple domains of the TNF-α promoter, however for maximum transactivation, the full-length 
promoter is required.   
 
Statement of Public Health Significance: By determining the details of HIV-1 Vpr and TNF-α 
interaction and the mechanisms for which they interact could reveal novel targets for the 
development of HIV-1 therapeutics in the fight against this epidemic.  
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1.0  CHAPTER ONE: INTRODUCTION 
1.1 THE AIDS PANDEMIC 
HIV/AIDS (Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome) is a 
disease that is now pandemic throughout the world. As of November 2007, the estimated number 
of infected individuals worldwide was 33.2 million, with an incidence of 2.5 million [1]. Sixty-
eight percent of these new cases occurred in sub-Saharan Africa. Over two million people died 
from AIDS in 2007 (Table 1). Since 2001, the number of infected individuals in Eastern Europe 
and Asia has increased by 150%. However, it has been reported that the overall prevalence of 
HIV has leveled off and the number of new infections has decreased [1]. 
 
In the twenty-five years since the discovery of the AIDS virus, the epidemic patterns 
have constantly evolved and the schematic maps continued to change colors.  Though every year 
the numbers have increased, the world is beginning to see the pay off from all the efforts put 
forth to help eliminate the devastation caused from this disease.  In countries in just about every 
region, there has been decreased prevalence in adults credited to signs of decreased risky 
behavior. Due to anti-retroviral therapy, HIV/AIDS mortality rate in many countries have 
declined in recent years [2].  Young women who attend antenatal have a lower prevalence that 
shows efforts are in fact beneficial in many of the most affected countries.  Many countries of 
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Sub-Saharan Africa such as Kenya and Zimbabwe, though still the region with the highest 
number of infected individuals, show steadying or declining numbers. 
 
Though success is apparent, much effort is still necessary.  In some countries, there have 
been reversals from declining to increasing numbers of affected individuals.  In areas like Latin 
America and the Middle East, there are existing stigmas and prejudices that inhibit proper 
surveillance and prevention and treatment efforts that need to be overcome [2].  With advances 
in this area, more accurate estimations will enable efforts tailored to the populations with most 
need. 
Table 1: Current Estimations of the HIV/AIDS Epidemic by Region (2007). 
World Region Total People Living with HIV 
New HIV 
Infections 
Adult 
Prevalence 
Total Deaths 
Due to AIDS 
Asia 4.9 Million 440,000 0.1% 300,000 
Sub-Saharan 
Africa 22.5 Million 1.7 Million 5.0% 1.6 Million 
Caribbean 230,000 17,000 1.0% 11,000 
Eastern 
Europe and 
Central Asia 
1.6 Million 150,000 0.9% 55,000 
North 
America and 
Western 
Europe 
2.1 Million 78,000 0.5% 32,000 
Latin 
America 1.6 Million 100,000 0.5% 58,000 
Middle East 
and North 
Africa 
380,000 35,000 0.3% 25,000 
Oceania 75,000 14,000 0.4% 1,200 
Total 33.2 Million 2.5 Million 0.8% 2.1 Million 
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2.0  CHAPTER TWO: BACKGROUND 
2.1 HIV-1: VIRUS STRUCTURE AND PATHOGENESIS 
The Human Immunodeficiency Virus type 1 (HIV-1), the causal agent of AIDS, is of the genus 
lentivirus and family Retroviridae.  The virus contains two copies of its single-stranded RNA 
genome which encodes for structural and functional proteins as well as the promoter that allows 
for transcription of viral genes in host cells (Figure 1).  This promoter is called the long-terminal 
repeat (LTR) and is flanked on each end of the coding region of the genome.  Structural proteins 
include Gag, Pol, and Env which also are involved in the pathogenesis of HIV-1.  Auxiliary or 
regulatory proteins comprise of Tat and Rev which are essential for viral replication.  Nef, Vif, 
Vpr, and Vpu are accessory proteins, which while not necessary for viral reproduction, do aid in 
the efficient replication and pathogenesis of the virus. 
 
Figure 1: The HIV-1 Genome. 
This schematic represents the HIV-1 genome including both structural and accessory 
proteins in which are flanked at either end by the HIV-1 LTR (long terminal repeat) 
promoter region. The structural proteins include gag, pol, and env while the remaining genes 
have various regulatory and accessory roles. 
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Figure 2 depicts the general HIV-1 virus life cycle.  Briefly, the virus attaches to the 
target cell surface via CD4 and the coreceptors, CCR5 or CXCR4, depending on the viral strain 
and target cell type, and the viral capsid is deposited into the cytoplasm [3, 4].  The viral RNA 
genome is reverse transcribed by virus encoded reverse transcriptase (RT) into double stranded 
DNA and translocalized to the nucleus where it integrates into the host genome.   
 
 
Figure 2: HIV-1 Viral Life Cycle.  
This schematic represents the basic steps in HIV-1 infection at the cellular level. 
 
Transcription of proviral DNA by the host RNA polymerase II produces full-length transcripts 
that are used to produce viral proteins or genomic RNA.  Env is translated in the endoplasmic 
reticulum and processed via the Golgi apparatus.  Virion components assemble at budding sites 
at the interface of the cellular plasma membrane. Maturation continues after egress with protein 
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modification by virus encoded protease. The target cells for HIV-1 are dividing CD4+ T-cells 
and non-dividing cells of the macrophage-phagocytic system [3, 4].  These cells are functionally 
disrupted and/or depleted during the course of infection, disrupting the host immune system. 
2.2 VIRAL PROTEIN R (VPR) 
As previously mentioned Vpr is one of the four accessory proteins of HIV-1 and is the focus of 
this thesis.  Vpr is described as a virion associated pleiotropic protein that has been associated 
with cell cycle arrest, apoptosis, immune regulation and evasion, translocation of the pre-
integration complex (PIC) into the nucleus, and viral gene transactivation [5-8].  Viral protein R 
(Vpr) is a 14-kDa protein that consists of ninety six amino acids and structurally contains three α 
helical domains flanked by amino and carboxyl terminal ends (Figure 3) [7].  
 
Figure 3: HIV-1 Vpr Protein Structure. 
This schematic depicts Vpr’s three alpha helices and the amino (N) terminal and carboxyl 
(C) terminal ends. Permission granted by Mary Ann Leibert, Inc. Publishers for use of this 
figure [7]. 
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These N-terminal and central regions have shown to play a role in the ability of Vpr to affect 
virion packaging, transcriptional activation and apoptosis [5, 7, 9]. The C-terminal region is 
arginine-rich and is also known to affect nuclear localization and the host cell cycle but it is not 
involved in virion incorporation [7, 9].   
 
The focus of this thesis is on Vpr and its role in transcriptional regulation. Vpr has been 
specifically associated with activation of the HIV-1 LTR promoter, though modestly, and of 
several other heterologous promoters [7, 10]. Vpr is known to interact with transcription factors 
SP1 and TFIIB, as well as NFκB and AP-1 in primary macrophages, and the host cellular factors 
glucocorticoid receptor (GR) as well as progesterone and estrogen receptors [7, 11-13]. Vpr has 
the ability to accomplish these functions in multiple contexts. It has been shown that Vpr exists 
not only as virion or cell associated, but also as free Vpr (cell and virus-free) [14]. This thesis 
will cover the transcriptional regulation of host cytokine expression by Vpr in its various forms. 
 
2.3 TUMOR NECROSIS FACTOR-ALPHA AND HIV-1 INFECTION 
It has been proposed that immune dysregulation is an effect caused by HIV-1 infection and that 
cytokines play a large role. Tumor necrosis factor-alpha, referred to as TNF-α, is a 
proinflammatory cytokine secreted by cells of myeloid lineage and is known to be involved in 
inflammation and apoptosis. TNF-α is synthesized as a 233 amino acid structure which is 
cleaved, and trimerizes into its active state and acts extrinsically through its receptors TNFR1 
and TNFR2 [13, 15, 16]. TNF-α matures and activates antigen presenting cells (APCs) as well as 
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other immune cells. Many studies have shown TNF-α and other inflammatory molecules to be 
associated with HIV-1 infection itself and also its associated anomalies such as lipodistrophy and 
AIDS-associated dementia.  More specifically, recent studies have shown relationships between 
HIV pathogenesis, viral proteins and TNF-α signaling especially in the central nervous system 
and the brain.   
 
It is generally accepted that TNF-α and TNFR levels are increased during the early 
phases of disease.  These levels correlate with viral load and CXCR4 expression, and inversely 
correlate with CD4+ T-cell counts [17, 18]. TNF-α produced by antigen-presenting cells (APCs) 
can cause secretion of other cytokines which affect infected and also bystander cells [19]. 
Interestingly, HIV-1 proteins including Nef, Vpr, and Tat have been proposed to act in a similar 
pathway as TNF-α, activating NFκB, AP-1 and mitogen-activated protein kinase (MAPK) to 
modulate cellular machinery [13, 18, 19]. This give strong evidence that TNF-α should be more 
closely studied in the context of HIV-1 infection.  
2.4 DC IMMUNOLOGY AND HIV-1 INFECTION 
During initial HIV-1 infection, especially when transmitted by sexual contact, it is understood 
that the first interaction between immune cells and virus occurs in the genital and oral mucosal 
surfaces [20].  Since dendritic cells (DCs) are located here, they are proposed to be one of the 
first cell types to encounter HIV.  Though DCs express low levels of CCR5 and CXCR4 
receptors, they have the ability to uptake virus due to their endocytotic characteristic as well as 
the expression of multiple C-type lectins such as DC-SIGN that are able to bind to HIV Env [21].   
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DCs travel into the lymphoid tissues where they act as antigen presenting cells to CD4+ and 
CD8+ T cells [20].  This is a proposed route of virus spread to the localized T-cell populations 
[20, 22].  HIV-1 is able to modulate normal DC function in infected individuals. For example, 
infected DCs express lower levels of surface co-stimulatory molecules such as CD80 and CD86 
and are significantly less efficient at inducing DC dependent T cell responses [20].   
 
HIV-1 Vpr is known to modulate normal DC phenotype and function as well as 
differentially regulate the expression of TNF-α. HIV-1 replication in DCs occurs very 
inefficiently.  However, cellular factors such as cytokines including TNF-α are able to influence 
viral replication in macrophages, DCs, and T cells.  Dendritic cells play a large role in the 
induction of a proinflammatory response by activation of cytokine signaling cascades.  However, 
there is a constant battle between proinflammatory molecules which aids in viral replication due 
to enhanced immune cell migration, and the viral suppressive activity of other cytokines [23]. 
For example, TNF-α enhances HIV-1 replication in macrophages and DCs as well trigger 
apoptosis of bystander T cell populations; however IL-15 is a potent inhibitor of the TNF-α 
apoptosis pathway [18, 19, 24].  IL-15 production is impaired during HIV-1 infection 
specifically in the presence of Vpr in DCs [24, 25].  Therefore, Vpr differentially regulates 
multiple cellular factors that can modulate normal immune function and the mechanisms 
involved are of importance for further understanding of HIV-1 infection. 
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3.0  CHAPTER THREE: THESIS AIMS 
HIV-1 Vpr differentially regulates cytokine expression during HIV-1 infection causing alteration 
of normal immune cell function. Several viral proteins, including Vpr are implicated in this 
immune modulation induced by HIV-1. Proinflammatory cytokine TNF-α is known to be 
regulated during early infection. We hypothesize those viral proteins that are a part of the virus 
particle, particularly HIV-1 Vpr, might have an impact on TNF-α production.  
 
AIM #1:   To investigate the effects of HIV-1 Vpr on the TNF-α production by dendritic  
 cells. 
A. Explore the effects of Vpr in its various forms on TNF-α production 
B. To map the domains of Vpr responsible for the induction of TNF-α in 
dendritic cells 
C. Determine whether infected cells and/or uninfected bystander cells are 
responsible for the increased TNF-α expression by Vpr 
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Vpr is known to transactivate viral and host cellular promoters as well as act as a co-activator of 
viral andgene expression during infection.  We hypothesize that regulation of TNF-α expression 
by HIV-1 Vpr might be mediated at the TNF-α promoter level. 
 
AIM #2:   To determine the domains of the TNF-α promoter involved in the 
transactivation of TNF-α expression by HIV-1 Vpr. 
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4.0  CHAPTER FOUR: MATERIALS AND METHODS 
4.1 CELL LINES 
HEK293T, 293FT, microglia, and HeLa T4 cells were maintained in DMEM (GIBCO) 
supplemented with 10% FBS, 1% L-glutamine (Cambrex), 1% penicillin-streptomycin (GIBCO), 
and 1% 10mM Non-Essential Amnio Acids (GIBCO);  medium for 293FT additionally 
contained 500µl/ml Geneticin.  293FT cells were purchased from Invitrogen as a component of 
the pLenti/V5 Directional TOPO Cloning Kit.  HEK293T cells were given by Dr. Michelle 
Calos, Stanford University, CA.  HeLa T4 cells were from the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, UNAID, NIH contributed by Dr. Richard Axel 
[26].  Microglia cells were provided by Dr. Bassel Sawaya at Temple University, Philadelphia, 
PA. 
 
Monocyte-derived dendritic cells (DC) were derived from human peripheral blood 
mononuclear cells (PBMC) from heparinized blood obtained from anonymous healthy, HIV-1 
negative, donors by the Central Blood Bank of Pittsburgh, PA with appropriate IRB approval.  
PBMC were isolated by Fycoll-Hypague gradient centrifugation.  From these cells, CD14+ 
monocytes were purified by positive selection using anti-CD14 monoclonal antibody-coated 
magnetic microbeads (Miltenyi Biotech, Auburn, CA) as the protocol suggests. Briefly, to obtain 
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monocyte-derived DC, CD14+ cells (0.5X106 cells/ml) were cultured in 60 mm culture plates in 
a total volume of 6 mL RPMI (GIBCO, Gaithersburg, MD) media containing 10% FBS, 1% L-
glutamine (Cambrex, Walkersville, MD), 1% penicillin-streptomycin (GIBCO), 25 ng/ml IL-4 
(R&D Systems, Minneapolis, MN) and 50 ng/ml recombinant GM-CSF (R&D Systems). Half 
the volume of media was replaced every second or third day with fresh media containing IL-4 
and GM-CSF throughout the entire culture period. 
4.2 CLONING 
The Vpr-EGFP lentiviral plasmid was cloned using the pLenti/V5 Directional TOPO Cloning Kit 
(Invitrogen).  The Vpr-EGFP fusion gene, previously constructed, was amplified by PCR using 
forward primer: 5’CACCATGGAACAAGCCCCAGAGA3’ and reverse primer: 
5’TTACTTGTACAGCTCGTCCAT3’ producing a blunt-end product for proper fusion to the V5 
epitope flag of the cloning vector.  The PCR product was transformed into One Shot® Stbl3™ 
competent cells, cultured in S.O.C. media for one hour, then plated on LB agar plates containing 
ampicillin (100µg/ml).  Single colonies were cultured in ampicillin containing media and DNA 
was screened by restriction digest analysis for positive clones.  The Vpr lentivirus plasmid was 
obtained by restriction digest of Vpr-EGEF lentivirus plasmid removing the EGFP fragment with 
Age I.  The EGFP lentivirus was obtained similarly.  
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4.3 TRANSFECTION METHODS 
4.3.1 Calcium Phosphate 
The calcium phosphate method was used for DNA transfection of HEK293T cell line.  Briefly, 
cells were cultured in 10mm dishes to approximately 75% confluency.  Four hours prior to 
transfection, old media was replaced with 6 ml DMEM supplemented with 10% FBS and cells 
were placed in 5% CO2. The transfection was conducted by adding DNA (up to 25µg) to 450µl 
water, then subsequently adding CaCl2 (50µl) and 50mM BES (BES, 250mM NaCl, 0.5mM 
Na2HPO4) (450µl).  The transfection mixture was allowed to incubate at room temperature for 30 
minutes.  The mixture was then added drop-wise to the cell media.  Twelve to 16 hours later, the 
cell media was removed and replaced with fresh complete media. 
4.3.2 Lipid-Mediated Transfection 
Lipid-mediated transfection method was performed using 293FT, HeLa T4, and Microglia cell 
lines.  Cells were plated in antibiotic-free media for approximately twelve hours prior to 
transfection to 90% confluency.  For a 12-well plate, DNA (1-2µg) was added to Opti-MEM 
(GIBCO) (50µl).  Lipofectamine 2000 transfection reagent (Invitrogen) (1µl) was added to Opti-
MEM (50µl) and incubated at room temperature for 5 minutes, then added to the DNA mixture.  
The DNA-Lipofectamine complex was incubated at room temperature for 20 minutes.  Post-
incubation, cell culture media was replaced with fresh antibiotic-free DMEM and the 
transfection mixture was added drop-wise to the culture.  The cells were incubated at 37ºC for 4-
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6 hours, then the medium was replaced with fresh DMEM supplemented with 10% FBS, 1% L-
glutamine, 1% penicillin-streptomycin, and 1% 10mM Non-Essential Amino Acids. 
4.4 VIRUS 
4.4.1 Virus Production 
HIV-1 NL43 and 89.6 wild-type and ∆VPR viruses were obtained by transfection of HEK293T 
cells with pNL43 or 89.6 WT or ∆VPR proviral plasmids by calcium phosphate method. Virus 
released in the supernatant was collected seventy-two hours post transfection. Lentiviruses were 
produced by lipid-mediated transfection of the specified lentiviral plasmid accompanied by the 
Virapower® Packaging Mix (Rev, Gag/pol, VSV/G) in the 293FT cell line. All viruses were 
purified by centrifugation and filtration to remove cellular debris, and concentrated by 
ultracentrifugation at 22,000 rpm for 1 hour at 4ºC.  Viral titer was determined through p24 
antigen ELISA. 
4.4.2 Virus Labeling 
NL43 wild-type and NL43 ∆VPR viruses were labeled directly with Cy5 mono-reactive dye as 
suggested by the manufacturer’s protocol (Amersham). Initial protein estimations of the virus 
samples were taken by Bradford protein assay. One milligram of total virus protein was 
dissolved in 1mL of 0.1M sodium carbonate buffer and then added to one vial of dye. This was 
mixed thoroughly by inverting the vial, and then incubated at room temperature mixing every ten 
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minutes. Labeled virus was separated from free dye through the use of a G-25 M Sephadex 
column (Amersham). Column was equilibrated with DPBS twice. Reaction mix was added to the 
column and further DPBS was added to allow flow through. Two bands were seen, the faster 
moving band was labeled virus, while the slower moving band was the free dye. Virus titer was 
measured by p24 antigen ELISA post-labeling. 
4.5 WESTERN BLOT 
For virus characterization, HEK293T and 293FT cells were derived from untransfected and 
transfected cells and virus pellet was obtained as described above.  Cells were washed twice with 
PBS and lysed in RIPA buffer containing 50mM Tris (pH 7.5), 150mM NaCl, 1% Triton-X100, 
1mM sodium orthovanadate, 10mM sodium fluoride, 1.0mM phenylmethyl-sulfonylfluoride, 
0.05% deoxycholate, 10% SDS, 0.07 trypsin inhibitor units/ml aprotinin, and protease inhibitors 
Leupeptin, Chymostatin, and Pepstatin (1 µg/ml; Sigma). Cell lysates were clarified by 
centrifugation and total cell lysates (50 µg) were separated on a SDS-PAGE gel, transferred to a 
membrane, and immunoblotted for with anti-HIV-1 p24 (NIH AIDS Research and Reference 
Reagent Program), anti-HIV-1 Vpr (gift from John Kappes, University of Alabama), and/or anti-
GFP (Abcam) for detection of mentioned proteins. Loading was based on protein concentration.  
 
Western Blots were also done on virus pellets to confirm the concentration of the p24 gag 
protein. Vpr was also detected in HIV-1 Vpr(+) virus pellets.  Pellets were separated on a SDS-
PAGE gel, transferred to a membrane, and the expression of the above mentioned proteins were 
detected as described before. 
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4.6 VPR PEPTIDES 
VPR peptides used in DC stimulation experiments were obtained through the AIDS Research 
and Reference Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 Consensus B VPR (15-
mer) Peptides - Complete Set. Sets used in these specific experiments were made by combining 
various 15-mer peptides to obtain desired sequence (Table 2).  
 
Table 2: HIV-1 VPR Peptides. 
 Peptide Sequence 
1-19 MEQAPEDQGPQREPHNEWT 
21-35 ELLEELKNEAVRHFP 
37-55 IWLHGLGQHIYETYGDTWA 
45-63 HIYETYGDTWAGVEAIIRI 
65-83 QQLLFIHFRIGCRHSRIGV 
81-96 IGVTRQRRARNGASRS 
 
DCs were isolated and cultured as previously described.  Four days after isolation, DCs 
were exposed to different Vpr peptides (100ng/ml).  Forty eight hours after stimulation, LPS was 
added or not added to the cell culture medium.  Cell supernatants were collected after an 
additional 24 hours and stored at -80ºC until analysis by TNF-α ELISA as described below.  
Values were compared to TNF-alpha production from stimulation with irrelevant Vif peptides 
obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, 
NIAID, NIH (HIV-1 Consensus B VIF (15-mer) Peptides - Complete Set). 
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4.7 RECOMBINANT PROTEIN 
Vpr recombinant protein was produced using the pET Duet vector and protein expression system 
(Novagen). Glutathione S-transferase (GST) recombinant protein was used as an irrelevant 
control protein. Both Vpr and GST were produced in E. coli following IPTG induction and 
purified according to the manufacturer’s instructions (Novagen). Bacterial contaminants were 
removed by high-performance liquid chromatography (HPLC) purification and absence of 
endotoxin was confirmed as described by our laboratory previously [19]. 
 
DCs were cultured as described before.  Recombinant Vpr or GST protein was added to 
the cells in various concentrations and incubated for 48 hours.  Cells were then treated with or 
without LPS for an additional 24 hours.  Supernatants were collected and used for cytokine 
analysis by TNF-α ELISA as described below. 
 
4.8 CYTOKINE ANALYSIS OF HIV-1 EXPOSED DC 
4.8.1 Detection of TNF-alpha by ELISA 
Dendritic cells were isolated and cultured as previously described.  Four days after initial culture, 
DCs were exposed to HIV-1 wild-type or HIV-1 ∆VPR.  After forty-eight hours post-
transduction, cells were stimulated with LPS (1µg/ml).  Twenty-four hours post LPS stimulation, 
supernatants and cells were collected for further analysis.  Cell debris was removed from the 
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supernatants by centrifugation.  Soluble TNF-α was measured in these supernatants by TNF 
ELISA Set as per manufacturer’s instructions (BD Biosciences). 
4.8.2 Flow cytometry 
DCs were treated as mentioned above.  For flow cytometry, cells were collected and washed two 
times with FACS buffer (PBS supplemented with 3% FBS). For surface staining to detect 
expression of IL-15, cells were stained with IL-15 antibody (Santa Cruz Biotechnologies) for 30 
minutes on ice. Cells were washed and conjugated with anti-IgG1-PE (Santa Cruz 
Biotechnologies) also on ice for 30 minutes. Cells were washed twice with FACS buffer to 
remove residual antibody.  Cells were fixed in 2% paraformaldehyde at 4ºC. 
 
For intracellular detection of TNF-α and/or p24, virus exposed cells were treated with 
GolgiStop® (BD Biosciences) in addition to LPS as described above.  This inhibits anterograde 
transport of cytokines from the golgi apparatus to the cell surface.  Cells were collected and 
washed two times with FACS buffer.  For detection of intracellular proteins, fixation and 
permeabilization was carried out using the Cytofix/Cytoperm kit (BD Bioscience).  The cells 
were incubated in the Cytofix/Cytoperm solution for 20 minutes at room temperature, followed 
by two washes with the Perm/Wash buffer (BD Bioscience).  Intracellular staining was 
performed at room temperature for one hour then washed with Perm/Wash and analyzed by flow 
cytometry in FACS buffer.  Antibodies used include anti-mouse TNF-PE (BD), anti-rat TNF-
APC (Abcam), and for p24 detection anti-K562-FITC (Beckman Coulter).  Analysis was done 
using the computer program, FlowJo.  
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4.9 TNF PROMOTER-LUCIFERASE ASSAY 
4.9.1 Promoter-Luciferase Constructs 
TNF-luciferase constructs were kindly provided by Dr. Bassel Sawaya, Temple University, 
Philadelphia, PA. Constructs were confirmed by enzyme digest and sequencing reactions. 
4.9.2 Luciferase Reporter Assay 
Cells were cultured in a 12-well plate format. TNF-α promoter luciferase constructs (1µg) were 
transfected using the lipid-mediated transfection method mentioned above. In microglia cells, 
pVPR or pcVector (pcDNA3.1/V5 HIS TOPO Expression Vector, Invitrogen), was co-
transfected with the luciferase construct. Twenty-four hours post-transfection, LPS (1µg) was 
added to the cells.  In HeLa T4 cells, transfection of the TNF-α promoter-luciferase constructs 
was performed by lipid-mediated transfection.  HIV-1 NL43 wild-type or ∆VPR (100ng p24 
equivalent per ml) was added in addition to PMA (20ng) and ionomycin (5µM) 24-hours post-
transfection. The assay was performed using the Luciferase Assay System (Promega) as the 
protocol suggested. Briefly, forty-eight hours post-transfection, culture medium was removed 
and discarded. Cells were washed with PBS and all liquid was removed.  Passive Lysis Buffer 
(200µl of 1X) was added to the cells and cell lysate was separated from cell debris by 
centrifugation.  Cell lysates (20µl) were added to Reporter Assay Substrate (100µl) and relative 
light units were detected by luminometer.  Transfection efficiency was normalized by co-
transfecting pEGFP with the promoter-luciferase constructs and determining equivalency by 
fluorescence microscope. 
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4.10 STATISTICAL ANALYSIS 
Results were analyzed using 1-tailed, paired student t-test using Microsoft Excel. P value less 
than ≤0.05 was considered as statistically significant. 
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5.0  CHAPTER FIVE: RESULTS 
5.1 AIM #1: TO INVESTIGATE THE EFFECTS OF HIV-1 VPR ON THE TNF-
ALPHA PRODUCTION BY DENDRITIC CELLS 
5.1.1 Characterization of Viruses 
To identify the effects of HIV-1 Vpr multiple virus constructs were used.  First, HIV-1 NL43 
(CXCR4-tropic) and 89.6 (dual tropic) viruses, and lentiviruses expressing Vpr or control protein 
(EGFP) were generated as described in the above section.  Characterization was completed for 
the presence of p24 Gag antigen as well as for Vpr using specific antibodies.  As seen in Figure 
4A, p24 Gag was detected by protein analysis of concentrated virus pellet by western blot.  
Presence or absence of Vpr was also determined by western blot. As expected, viruses containing 
Vpr mutations had no trace of the protein.  p24 Gag was also detected in virus exposed dendritic 
cells by flow cytometry confirming the occurrence and efficiency of virus transduction (Figure 
4B).  Equal to reduced transduction was typically seen by HIV-1 Vpr(-) virus compared to Vpr-
containing wild type virus. 
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 A. 
   
B. 
Figure 4: Viral protein Characterization of Viruses.  
(A)Virus pellets analyzed for the presence or absence of p24 Gag and Vpr by western blot, 
(B) Virus transduction in exposed DCs determined by flow cytometry after intracellular 
staining for Gag p24 antigen. 
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 Lentiviruses expressing EGFP were further characterized by fluorescence microscopy in 
293FT cells during virus production (Figure 5). Expected patterns were observed as the pLenti-
EGFP transfected cells showed protein expression localized in the cytoplasm.  Cells transfected 
with pLenti-Vpr-EGFP were seen with expression in both the cytoplasm and the nucleus. This 
would occur due to Vpr nuclear localization with the fusion protein remaining intact. 
 
 
Figure 5: Characterization of Vpr-EGFP expressing lentivirus constructs by 
immunofluorescence. 
Characterization of lentiviral constructs was performed by transfecting 293FT cells with the 
appropriate plasmid, followed by fluorescent microscopy. The cell nucleus was stained with 
Dapi stain (blue) and EGFP expression (green) was observed using FITC filters. Localization 
of protein expression can be seen with the overlay. 
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5.1.2 Induction of TNF-α by HIV-1 Vpr 
Vpr is known to play a role in activation of viral protein expression and signaling cascades that 
elicit proviral and antiviral responses. In dendritic cells, our laboratory has shown that HIV-1 
Vpr(+) virus exposure causes an upregulation of TNF-α mRNA synthesis and protein expression 
[19]. Similar effects were observed in DCs exposed to noninfectious virus containing Vpr as well 
as Vpr-GST recombinant protein.  This section reiterates previous findings and gives further 
insight to Vpr’s role in TNF-α production by dendritic cells in regards to its multiple forms and 
protein domains.  
5.1.2.1 Affect on TNF-α by Vpr in the Context of HIV-1 Infection 
To assess Vpr and its ability to induce TNF-α expression in the context of infection, DCs were 
cultured as described and exposed to VSV-G pseudotyped HIV-1 NL43 wild-type or Vpr 
defective virus (Figure 6).  VSV-G enables the NL43 variant to be taken up by dendritic cells 
due to the X4 tropism of the viral strain and low expression of the CXCR4 co-receptor on DC 
surfaces. TNF-α was detected in the DC supernatant by ELISA and intracellularly by flow 
cytometry. There was an average two fold increase in TNF-α production by NL43 Vpr(+) virus 
infected DCs upon LPS stimulation. Similar results were observed in six separate donors. A 
similar increase in TNF-α expression was also detected by flow cytometry with over twenty 
percent more in cells exposed to Vpr(+) virus.   
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 Figure 6: Increase in TNF-alpha expression by HIV-1 Vpr in the context of virus infection. 
(A) DCs were exposed to NL43 Vpr(+) or NL43 Vpr(-) virus for 48 hours then stimulated 
with LPS for an additional 24 hours.  Supernatants were then collected for analysis by TNF-
α ELISA. Solid lines indicate donor averages. (B) DCs were exposed to NL43 Vpr(+) or 
NL43 Vpr (-) for 48 hours then stimulated with LPS in the presence of GolgiStop for 6 
hours.  Cells were permeablized for intracellular staining of TNF-alpha and expression was 
detected by FACS analysis (representative of six donors).   
 
 
Similar experiments were done next using HIV-1 89.6 wild-type and 89.6 ∆Vpr viruses 
(Figure 7).  HIV-1 89.6 viral strain is CCR5/CXCR4 dual-tropic and have the ability to infect 
macrophages without VSV-G, however to keep consistency between experiments, these viruses 
were pseudotyped as well.  After virus transduction of DC and stimulation with LPS as 
previously mentioned, TNF-α was measured intracellularly or by secretion in the cell 
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supernatants.  On average, there was a 2.7 fold increase in TNF-α secretion by Vpr containing 
virus compared to in counterpart, which was statistically significant.  Minimal two-fold 
differences in TNF-α expression were also consistently seen by intracellular staining.  Together, 
these results indicate a similar induction of TNF-α expression by Vpr independent of the HIV-1 
viral strains used to transduce DCs. 
 
 
 
Figure 7: Increase in TNF-alpha expression by HIV-1 Vpr in the context of 89.6 infection.  
(A) DCs were exposed to 89.6 Vpr(+) or 89.6 Vpr(-) for 48 hours then stimulated with LPS 
for an additional 24 hours.  Supernatants were then collected for analysis by TNF-α ELISA.  
Results include standard error across two separate donors. (B) DCs were exposed to 89.6 
Vpr (+) or 89.6 Vpr (-) for 48 hours then stimulated with LPS in the presence of GolgiStop 
for 6 hours.  Cells were permeablized for intracellular staining of TNF-alpha and expression 
was detected by FACS analysis (representative of two donors).   
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To control for specificity of this effect seen on TNF-α, production of IL-15 by DCs was 
also detected by flow cytometry.  In this case, an opposite effect on IL-15 expression on the DC 
cell surface was observed by the same donors used for the previous experiments as shown in 
Figure 8.  As expected, induction of IL-15 expression in the presence of HIV-1 Vpr was 
decreased in comparison to Vpr defective virus.  Similar results were observed when using either 
virus construct. This indicated that the increase in TNF-α expression by HIV-1 Vpr is a specific 
effect. 
 
 
Figure 8: Effect of HIV-1 Vpr IL-15 expression. 
DCs were obtained as described previously and exposed to HIV-1 Vpr(+) or HIV-1 Vpr(-) 
virus for 48 hours then stimulated with LPS for an additional 24 hours.  Cells were stained 
for surface IL-15, fixed and analyzed by flow cytometry. 
 
5.1.2.2 Affect on TNF-α by de novo synthesized Vpr 
Next, to assess the role of de novo synthesized HIV-1 Vpr and its affect on the production 
of TNF-α in DCs, cells were infected with lentiviruses expressing Vpr alone, the Vpr-EGFP 
fusion protein or EGFP alone, which was used as a control.  By using a lentiviral construct, the 
encoded viral genome has the ability to integrate into the infected cell’s genome and be 
expressed in this fashion.  For initial infection ability, virus constructs were packaged with Gag, 
Rev, and VSV-G Env. As Figure 9 displays, de novo synthesized Vpr increased the production of 
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TNF-α as compared to EGFP alone.  Vpr expressed as a fusion with EGFP induced an average 
1.6 fold increase in TNF-α secretion by DCs where as Vpr alone induced a significant 3.5 fold 
difference compared to EGFP alone (Figure 9A).  An increase was also seen by intracellular 
staining for TNF-α (Figure 9B).  This gives insight to the difference de novo synthesis of viral 
proteins can make on the pathogenesis of HIV-1. 
 
 
 
Figure 9: Increase in TNF-alpha production by de novo synthesized HIV-1 Vpr. 
(A) DCs were infected with Vpr and/or EGFP containing lentiviruses for 48 hours and 
additionally with LPS for 24 hours.  After stimulation supernatants were collected for TNF-
α quantification by ELISA.  (B) DCs were infected with Vpr or EGFP containing lentiviruses 
for 48 hours and stimulated with LPS in the presence of GolgiStop for 6 hours.  Cells were 
permeablized and quantified for TNF-α by intracellular staining and FACS analysis 
(representative of three separate donors). 
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5.1.2.3 Effect on TNF-α Expression by Recombinant Vpr Protein 
To evaluate the effect of TNF-α expression by cell and virion free Vpr, DCs from three 
separate donors were exposed to multiple concentrations of recombinant Vpr and GST proteins 
in culture (Figure 10). As the concentrations increased, ultimately so did the level of TNF-α 
released by the DCs exposed to Vpr whereas the TNF-α secretions remained minimal when 
exposed to GST protein. Interestingly, there was a significant jump between exposure to 1µg/ml 
and 10µg/ml free Vpr which then tapered off up to 50µg/ml. Notably, the values measured for 
TNF-α after Vpr protein exposure were greatly increased compared to Vpr in the context of 
infection or de novo protein synthesis indicating a strong role of free Vpr during infection. 
 
 
Figure 10: Increase in TNF-alpha production by recombinant Vpr protein.   
DCs were cultured as described and exposed to Vpr or GST recombinant protein for 48 
hours and stimulated with LPS for an additional 24 hours in 1ml of culture.  Supernatants 
were collected and analyzed by TNF-α ELISA.  Results include standard error between 
three separate donors. 
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5.1.2.4 Domains of Vpr Involved in TNF-α Production 
Next, to identify the domains of Vpr involved in the induction of TNF-α, human DCs were 
exposed to different Vpr peptides (15-mers). TNF-α was measured in the cell supernatants. TNF-
α production was compared to that of irrelevant Vif peptides. Between the Vpr peptide groups, 
slight fluctuations were seen but no significant difference was measured (Figure 11). Results 
were consistent among five separate donors. The six domains studied show each set are equally 
involved in the ability of Vpr to induce the production of TNF-alpha. 
 
Figure 11: TNF-alpha production by Vpr Peptides. 
DCs were exposed to 100µg of the indicated peptides for 48 hours. Cells were stimulated 
with LPS and supernatants were collected after 24 hours. Fold induction calculated by TNF 
production induced from 100ug Vpr peptides compared to production from irrelevant Vif 
peptides.  
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5.1.3 Differentiation of DC Populations Responsible for Enhanced TNF-α Production 
5.1.3.1 Intracellular staining for p24 and TNF-α 
It has been established that HIV-1 infection can cause inflammatory affects in those specific cells 
or in uninfected bystander cells. Using DCs from the same donors as previous experiments, it 
was sought out to distinguish whether the induction of TNF-α expression by Vpr occurred in 
infected cells or bystander cells. Cells were transduced with virus and stimulated with LPS then 
stained intracellularly for TNF-α or p24 Gag antigen, or both, and analyzed by flow cytometry 
(Figure 12). In Figure 12A, the top panel shows that TNF-α production was detected when 
stimulated cells were singly stained. The middle panel shows a shift of p24 positive cells when 
exposed to virus, however, in those only exposed to LPS as well. When stained for both markers, 
a similar pattern is seen in the uninfected cells with a p24 positive shift indicating nonspecific 
binding of the p24 antibody. This was seen in multiple donors, and without an alternative p24 
antibody available, the same results were revealed after changing other assay parameters (Figure 
12B). With this nonspecific p24 antibody staining, no conclusion could be drawn as to the 
percentages of infected/exposed or uninfected cells, nor which cells were the dominant producers 
of TNF-α. 
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 A. 
 
 
B. 
Figure 12: Dual staining of HIV-1 virus exposed DCs for TNF-alpha and p24 Gag.  
DCs were cultured and exposed to HIV-1 89.6 WT or HIV-1 89.6 ∆Vpr for 48 hour then 
exposed to LPS in the presence of GolgiStop for six hours.  Cells were permeablized and 
stained for (A) TNF-α, p24 or (A and B) both and analyzed by flow cytometry. 
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5.1.3.2 Cy5 labeled NL43 virus 
To attempt to distinguish cell type specificity for the enhanced production of TNF-α in virus 
exposed DCs, a second methodology was used.  VSV-G complemented NL43 Vpr(+) and NL43 
(Vpr-) viruses were labeled using Cy5 dye as described in the Materials and Methods section.  
Cy5 can be detected by the APC channel of the cytometer and therefore can signify infected 
cells.  Cy5-labeled virus was quantified by total protein due to p24 Gag antigen levels being low 
to undetectable after labeling by p24 ELISA.  After virus exposure and LPS stimulation, cells 
were stained intracellularly for TNF-α and analyzed by flow cytometry.   
 
First, to determine the ability of DCs to uptake this virus, multiple concentrations of the 
virus were added to the cells. Shown in Figure 13, as the added virus concentration increased, the 
virus uptake also increased reaching close to 100% Cy5+ positive cells, indicating the ability of 
the cells to uptake this virus and do so in a dose dependent manner. 
 
 
Figure 13: DC uptake and TNF-α production by Cy-5 labeled virus.   
DCs were cultured as described and exposed to Cy-5 labeled HIV-1 WT or ∆Vpr for 48 
hours and stimulated with LPS in the presence of GolgiStop for 6 hours.  Cells were 
harvested, permeablized and stained intracellularly for TNF-α and analyzed by flow 
cytometry (representative of at least three separate donors). 
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Next, to assess the TNF-α production of DCs after Cy5-labeled virus exposure, the 
secretion of this cytokine was detected by ELISA (Figure 14A). At each concentration, both 
HIV-1 Vpr(+) and HIV-1 Vpr(-) virus exposure induced the expression of TNF-α at similar 
levels as non-labeled virus shown previously. Interestingly, a large difference between the two 
viruses was only seen when exposed to a higher virus dose. This is likely due to the increased 
concentration of p24 Gag present in this higher dosage.  Due to this, 250ng was used in further 
experiments where DCs were stained for TNF-α for analysis by flow cytometry.  As seen in 
Figure 14B, TNF-α was detected only in the double positive population demonstrating that 
responsible DC population is virus infected/exposed. This shows that virus exposed cells might 
be the primary producers of TNF-α.  
 
 34 
  
 
Figure 14: Detection of Soluble TNF-α in DC supernatants.   
Cells were cultured as described and exposed to Cy-5 labeled virus for 48 hours and 
stimulated with LPS for an additional 24 hours.  (A) Supernatants were collected and the 
presence of soluble TNF-α was detected by ELISA.  (B) Cells were stimulated with LPS for 
six hours with GolgiStop and stained for TNF-α and analyzed by FACS analysis 
(representative of three donors). 
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To control for the increase in TNF-α seen by exposure to Cy5 labeled HIV-1 WT, IL-15 
was detected by flow cytometry as well. The expected trend of decreased surface IL-15 in the 
presence of labeled HIV-1 Vpr(+) virus compared to Vpr-defective virus was seen, representing 
that TNF-α production by Vpr is a specific effect (Figure 15).  This also shows evidence of virus 
functionality after the labeling process. 
 
 
Figure 15: IL-15 modulation by HIV-1 Vpr (+) and Vpr (-) Cy-5 labeled virus.  
DCs were cultured as described and exposed to Cy-5 labeled HIV-1 WT or HIV-1 ∆Vpr 
virus (250µg total protein/ml) for 48 hours and additionally stimulated with LPS for 24 
hours.  Cells were harvested and stained for surface IL-15 expression which was quantified 
by FACS analysis. 
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5.2 AIM #2: TO DETERMINE THE MECHANISMS IN THE REGULATION OF 
TNF-ALPHA EXPRESSION BY HIV-1 VPR 
5.2.1 Introduction 
In our laboratory and in others, it has been well established that HIV-1 Vpr transactivates several 
viral and cellular genes [12, 19]. We also know that Vpr is involved in the upregulation of TNF-
α as virion associated and as free Vpr at the transcriptional level [19]. To further understand the 
transcriptional regulation of TNF-α by Vpr, transactivation assays were performed using full-
length and deletion mutant TNF-α promoter constructs placed upstream of the firefly luciferase 
reporter gene. Upon activation of the TNF-alpha promoter, production of the luciferase 
enzymatic protein occurs and can be detected using a luciferase substrate kit. Transactivation 
was measured by relative light units (RLU). 
5.2.2 Assay Parameters 
To investigate Vpr and the transactivation of the TNF-alpha promoter, we used a full length and 
deletion mutant promoter sequences constructed directly upstream of firefly luciferase gene as 
shown (Figure 16).  The full length promoter construct is -958bp and includes transcription 
factors SP1 and NFκB which have been shown previously to interact with Vpr. 
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A. 
B. 
 
Figure 16: Representation of TNF-alpha Promoter and Deletion Mutants.   
(A) Sequences highlighted in green indicate those that are homologous to the full-length 
promoter (-958) ending at the TATA box. (B) A schematic depicting the promoter constructs 
and their transcription factor orientations. 
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Initial experiments were performed in order to determine the optimal DNA concentration 
of Vpr plasmid for transfection, which will result in optimal transactivation of the TNF-alpha 
promoter without inducing apoptosis. The concentration of the full length promoter-luciferase 
construct (-958) remained constant (1µg) and the concentrations of the Vpr expression plasmid 
(pVpr) or an empty vector plasmid (pVector) ranged (0.1 µg, 0.2 µg, 0.5 µg, 1.0 µg) as seen in 
Figure 17 and 18.  For consistency, LPS was used for stimulation as transactivation could not to 
be distinguished with expression plasmids alone (data not shown). PMA and ionomycin was 
used for stimulation in HeLa T4 cells because they do not express TLR4 and are unresponsive to 
LPS.   
 
In macrophage derived microglia cells (Figure 17A), promoter activation by Vpr 
remained steady but greatly dropped above 0.5µg. This could be a result of cytotoxicity by Vpr 
at higher concentrations as a great amount of cell death was observed in culture by microscopy. 
To further analyze the lower DNA concentrations for optimization, transactivation by the empty 
expression vector was subtracted from that by pVpr.  This revealed 0.5µg to be the best for use 
in these experiments.  Similar results were observed in HeLa T4 cells, with transactivation by 
Vpr greatly decreasing at 1.0 µg and 0.5µg showing to be the optimal DNA concentration of 
pVpr or pVector for transfection (Figure 18).  This selected concentration was used in all further 
promoter transactivation experiments. 
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Figure 17: Assay Parameter Development using the full length TNF-α promoter in Microgila 
cells.  
(A) Various concentrations of pVpr or pVector were cotransfected with the -958bp full 
length TNF-α promoter-luciferase construct.  Forty eight hours post transfection, promoter 
transactivation was detected by luciferase reporter assay.  (B) Transactivation by pVpr was 
measured by subtracting the RLU values observed in pVector transfected lysates from pVpr 
transfected lysates. 
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Figure 18: Transactivation of TNF-alpha by Various Concentrations of HIV-1 Vpr in HeLa T4 
cells.  
HeLaT4 cells were co-transfected with the TNF promoter and varying concentrations of 
pVpr or pVector. (A) Forty-eight hours post-transfection, cell lysates were collected and 
promoter transactivation was determined as RLU.  (B) Transactivation by pVpr was 
measured by subtracting the RLU values observed in pVector transfected lysates from pVpr 
transfected lysates. 
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5.2.3 Promoter activation by HIV-1 Vpr in Microglia cells 
Due to the apparent induction of TNF-alpha in the presence of Vpr, and Vpr’s ability to regulate 
host and viral gene expression at the transcriptional level, it was important to study the 
transcriptional regulation of the TNF-α promoter.  Transactivation assays were performed using 
a full length and four additional truncated promoter constructs.  As shown in Figure 19, promoter 
activation by Vpr occurs at the highest level when the full length promoter is present. Fold 
activation of the truncated promoters still occurred, though reduced by half. These results point 
out that in order for Vpr to fully activate TNF-α production, presence of the full length promoter 
is necessary. 
 
Table 3: TNF-α Promoter Activation (RLU) in Microglia Cells. 
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 Figure 19: Fold activation of the TNF-α promoter by HIV-1 Vpr in Microglia cells.   
Cells were co-transfected with said promoter construct and pVpr or pVector expression 
plasmids.  Cells were stimulated 24 hours post-transfection with LPS and cell lysates were 
collected.  This figure is representative of five independent experiments. 
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5.2.4 Promoter induction by HIV-1 Vpr in HeLa T4 cells 
To further look at the activation of the TNF-α promoter by HIV-1 Vpr, a second transactivation 
assay was performed using the HeLa T4 cell line and whole virus. HeLa T4 cells express CD4 
and can be productively infected. This allowed for insight in the promoter’s interaction with Vpr 
in the context of infection. Experiments were completed in the same manner; however promoter 
constructs were transfected alone. HIV-1 Vpr(+) or HIV Vpr(-) was added with PMA and 
ionomycin 24 hours post-transfection. 
 
Table 4: TNF-α Promoter Transactivation (RLU) in HeLa T4 Cells. 
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Interestingly, transactivation was apparent with the full-length promoter as well as the -732bp 
and -615bp truncated mutants, but was not seen in the -91bp and -25bp mutants (Figure 20).  
Fold increase of transactivation by HIV-1 Vpr(+) compared to HIV-1 Vpr(-) is shown below. 
This supports previous experiments in that Vpr can induce TNF-α production by interaction with 
the downstream domains of the promoter however, maximum activation occurs in the presence 
of the full length promoter. 
 
 
Figure 20: Fold activation of the TNF-α promoter by HIV-1 Vpr in HeLa T4 cells.  
Cells were co-transfected with said promoter construct.  Cells were stimulated 24 hours 
post-transfection with PMA and ionomycin in addition to NL43 HIV-1 WT or ∆Vpr and cell 
lysates were collected.  This figure is representative of three independent experiments. 
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6.0  CHAPTER SIX: DISCUSSION 
In the more than twenty-five years since the start of the HIV/AIDS epidemic, scientists have 
faced constant challenges in discovering therapeutics and developing an effective vaccine.  One 
large barrier has been the ability of viral proteins to interact with host encoded components.  This 
can occur through direct interaction or indirectly by signaling.  It has been proposed that this is a 
possible factor for viral pathogenesis and its ability to invade immunologically privileged areas 
of the body including the lymph nodes and the brain. TNF-alpha has proved to be an important 
component in HIV-associated dementia in AIDS patients as well as other ailments like 
rheumatoid arthritis and advancement of opportunistic infections [13, 27-29].  Vpr has also been 
found in brain tissue of infected patients [30]. This provides important relevance for 
understanding how HIV-1 Vpr affects TNF-α and the cell types that are involved. 
 
As seen in Figures 6, 7, 9, and 10, it is apparent that HIV-1 Vpr plays a role in the 
induction of TNF-α in dendritic cells. The levels of TNF-α detected by ELISA and flow 
cytometry are significantly increased in the presence of Vpr containing virus or recombinant Vpr 
protein compared to the absence of functional Vpr.  However, this was not observed unless cells 
were additionally stimulated by LPS. This could indicate that Vpr effects TNF-α by interaction 
with the Toll-like Receptor 4 (TLR4) signaling cascade for which LPS acts. Alternatively, Vpr 
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might act as a coactivator of TNF-α transactivation, as shown previously for other cellular 
factors [7, 31]. 
 
To identify the domains of Vpr responsible for the induction of TNF-α, monocyte derived 
DCs were exposed to six peptide pools covering the 96-amino acids of the Vpr protein.  In this 
setting, there was no significant difference between the levels of expression of soluble TNF-α in 
the presence of these peptide subsets in comparison to that induced by irrelevant peptide 
exposure (Figure 11).  This indicates that Vpr has multiple domains that have a role in increased 
TNF-α expression in dendritic cells.  It would be interesting to compare this data to TNF-α 
production by intact Vpr and to also look at these peptide sets structurally to see if the 
conformation plays a role it their ability to induce this effect. 
 
Next, we attempted to identify the specific population of the monocyte-derived DC 
cultures responsible for the increase in TNF-α production. Because it has been previously shown 
that TNF-α production by HIV-1 exposed, particularly HIV-1 Vpr(+) virus, DCs affects 
bystander T-cell subsets, it is unknown if DCs are acting from infection or simply exposure to 
virus. If deciphered, this would also allow for further understanding of the overall immunology 
of dendritic cells during HIV-1 infections and the effects they may have on each other and on 
other cells.  We were unable to conclusively determine the DC subset responsible for the 
enhanced TNF-α in the context of infection by intracellular staining however by using Cy-5 
labeled virus, results indicate that TNF-α production is enhanced in virus exposed cells (Figure 
14).   
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Issues with intracellular staining were addressed in multiple ways in order to produce 
dependable results.  First, cells were stained with TNF-α and p24 (Gag) antibodies 
simultaneously.  The p24 antibody was staining cells not exposed to virus and therefore showed 
nonspecific binding. This was addressed by staining DCs in a step-wise fashion however, either 
way, p24 was the dominant signal seen using a flow cytometer.  Because the p24 and TNF-α 
antibodies were both anti-mouse and there is no alternate antibody for p24 available, an anti-rat 
antibody for TNF-α was used in replacement.  This and use of alternate permeablization methods 
did not change the outcome. Further assays need to be developed to specifically differentiate 
infected or uninfected DCs and their separate cytokine profiles. 
  
 The Cy5 labeled viruses were used as an alternative way to detect infected cells by flow 
cytometry allowing intracellular staining for TNF-α without the competition of any other 
antibody.  Though TNF-α producing Cy5 positive cells were able to be detected, several 
limitations inhibit us into drawing conclusions.  One factor is that during the labeling process, 
the total protein detectable in the virus diminished as well as p24 levels becoming low.  
Therefore the amount of actual virus used was predictably less than in previous experiments.  
Another issue was that the DCs in culture became increasingly positive for Cy5 with increased 
added virus. This was expected, however, since the 250µg was used in the later studies, it did not 
allow us to look at the unexposed DC population.  Also, the overall TNF-α induction was low in 
comparison to previous experiments.   
 
Another aspect of HIV-1 Vpr and its differential regulation on TNF-α production can be 
addressed by determining the domains of the TNF-α promoter involved in activation.  To do this, 
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we first analyzed TNF-α promoter activation by Vpr using a luciferase reporter assay in two 
ways.  First, TNF-α promoter-luciferase constructs were co-transfected with a Vpr or empty 
expression plasmid in a monocyte derived cell line.  An increase in promoter activation was 
observed using all promoter constructs by Vpr; however the strongest signal was seen in the 
presence of the full length TNF-α promoter.  This is probably due to the lack of required 
transcription factors of the promoter or simply the dysfunction of the promoter itself due to its 
truncations. 
 
To determine whether a similar effect could be observed during infection as well, another 
luciferase reporter assay was performed using the TNF-α promoter-luciferase construct 
transfected in HeLa T4 cells which are easily transfectable as well as infectable due to its 
expression of the HIV-1 receptor CD4.  After transfection, cells were infected with HIV-1 NL43 
WT or NL43 ∆Vpr virus (100ng/ml).  Activation of the TNF-α promoter by Vpr containing virus 
was up to four fold greater than that of Vpr deficient virus.  Notably, transactivation was not 
observed when using the -91bp and -25bp promoter mutants. This reiterates that the full length 
TNF-α promoter is important for TNF-α production especially that induced by HIV-1 Vpr. 
Transcription factors Sp1 and NFκB might be involved in this transactivation.  To further look at 
the specific interactions between the TNF-α promoter, experiments should be done using the 
promoter luciferase assay using various Vpr mutants as the method of activation. 
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7.0  CHAPTER SEVEN: FUTURE DIRECTIONS 
It is clear that HIV-1 Vpr upregulates the expression of TNF-α in dendritic cells. However, it is 
still not clear whether this effect is seen primarily in the exposed or bystander DC population. In 
order to determine the particular DC population(s) responsible for the TNF-α production induced 
by HIV-1 Vpr, other methods can be used.  One possible alternative could be to develop other 
virus labeling methods that are specific for viral proteins such as p24 Gag; a sort of backwards 
approach to traditional staining methods for flow cytometry.  This way cells positive for the label 
could confidently be said as infected and not just randomly engulfing any labeled protein.  
Another approach that our laboratory has been working on is to make noninfectious virus-like 
particles (VLPs) containing Gag-EGFP, Vpr, and VSV-G by plasmid co-transfection. This 
method, theoretically, would be an ideal way to answer this question.  However, there has been 
some difficulty with seeing a strong EGFP signal after DC uptake by flow cytometry under the 
FITC channel (data not shown).  With successful troubleshooting of this method and use of other 
virus tracking technology, our question will be answered. 
 
To further identify the specific domains of HIV-1 Vpr and the TNF-α promoter involved 
in TNF-α transactivation, we will combine the two approaches shown here. Cells can be 
transfected with the TNF-α promoter luciferase constructs along with various Vpr mutant 
molecules. This can help further identify the domains of HIV-1 Vpr based on differential TNF-α 
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promoter induction. To assess the TNF-α promoter more in depth, gel shift assays using specific 
transcription factor motifs should be done to understand the specific transcription factors 
necessary for transactivation. 
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